Private Equity
Location
Rotterdam, The Netherlands
Boston, MA, USA
Private Equity
All Portfolio items
See full Private Equity portfolio
Viroclinics Biosciences is a leader in diagnostic and clinical-trial services. It is one of the few labs in the world able to perform highly complex, specialized diagnostic and preclinical studies in the field of virology. Viroclinics operates globally as the preferred virology testing laboratory for top-ten biopharmaceutical companies.
Gilde acquired a majority share in 2013. During Gilde ownership Viroclinics developed new services for the biopharmaceutical industry, expanded its facilities and tripled its revenues. Viroclinics was sold in 2017 to Parcom Capital.
More Viroclinics Biosciences news
d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the
Gilde Healthcare Services acquires majority share in Viroclinics Biosciences from Erasmus MC
Private Equity
Jecture
Jecture focuses on designing and contract manufacturing tailor-made, complex cannulas and cannula systems for pharmaceutical and medical applications. Headquartered in Germany, the group consists of the two well-established companies Acti-Med and EUROPIN – both with more than 25 years of
Private Equity
Detax
DETAX is a leading global supplier of biocompatible silicones and light-curing 3D resins for medical applications in the dental and audio sectors. Based in Germany, it supplies its products via original equipment manufacturers (OEMs) to dental practices, dental laboratories, audiologists,
Private Equity
Symeres
Symeres, previously known as Mercachem and Syncom, is a leading mid-sized European contract research organization (CRO) for integrated outsourced drug discovery services. Symeres focuses on serving smaller and midsized players with the quality and professional standards of larger CROs, enabling
